About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
UvragTn(pb-Act-RFP)1.100107015-HRAZhu
transposon insertion 1.100107015-HRA, Yuan Zhuang
MGI:5635118
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
hm1
UvragTn(pb-Act-RFP)1.100107015-HRAZhu/UvragTn(pb-Act-RFP)1.100107015-HRAZhu involves: FVB/NJ MGI:5695487


Genotype
MGI:5695487
hm1
Allelic
Composition
UvragTn(pb-Act-RFP)1.100107015-HRAZhu/UvragTn(pb-Act-RFP)1.100107015-HRAZhu
Genetic
Background
involves: FVB/NJ
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
UvragTn(pb-Act-RFP)1.100107015-HRAZhu mutation (0 available); any Uvrag mutation (41 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cardiovascular system
• by 10 months of age, the cross-sectional area of individual cardiomyocytes is significantly increased relative to wild-type controls
• by 10 months of age, mutant hearts appear to be larger than wild-type
• by 10 months of age, mutant hearts show increased interstitial cardiac fibrosis relative to wild-type controls
• at 10 months of age, mutant hearts accumulate autophagosomes and autophagic flux, based on changes in LC3 II protein levels elicited by chloroquine treatment, is impaired
• by 10 months of age, ejection fraction (EF) and percent fractional shortening (%FS) are reduced, suggesting impaired cardiac function
• by 10 months of age, the end-diastolic left ventricular dimension (LVEDD) and the end-systolic left ventricular dimension (LVESD) are significantly increased relative to wild-type controls
• homozygotes are viable, fertile, and developmentally normal but develop age-related cardiomyopathy, evident by 10 months of age
• no alterations in cardiac structure are noted at 2 and 6 months of age
• immunohistochemical staining of mutant hearts revealed that inflammatory cell markers CD45 (leucocytes) and CD45R (B cells) are significantly increased relative to wild-type hearts
• heart inflammation is already detectable at 6 months of age when cardiac structure and function are normal

cellular
• by 10 months of age, mutant hearts show increased interstitial cardiac fibrosis relative to wild-type controls
• at 10 months of age, mutant hearts display accumulation of lysosomal markers LAMP-1 and LAMP-2, suggesting that impaired autophagosome clearance is associated with increased lysosome numbers
• in contrast, cathepsin D, a lysosomal protease, is not significantly increased in mutant hearts
• at 10 months of age, mutant hearts accumulate autophagosomes, as shown by enhanced protein abundance of LC3 II; LC3 immunofluorescence and ultrastructural analysis confirmed accumulation of autophagic vacuoles in mutant hearts
• p62 (a marker for autophagic flux), is significantly increased in mutant hearts, indicating impaired autophagic flux
• the observed increase of LC3 II protein levels in mutant hearts is not further enhanced by treatment with chloroquine (an inhibitor of autophagosome-lysosome fusion)
• mutant MEFs show significantly increased LC3 II protein levels; however, the increase in LC3 II protein levels is not further enhanced by bafilomycin A1 (an autophagosome-lysosome fusion inhibitor), suggesting that autophagic flux is impaired in mutant MEFs
• ultrastructural analysis of mutant MEFs revealed clustered double-membrane autophagosomes and complex vacuoles containing multiple layers of membrane
• by 10 months of age, mutant hearts show significantly increased apoptosis, as shown by TUNEL analysis

immune system
• immunohistochemical staining of mutant hearts revealed that inflammatory cell markers CD45 (leucocytes) and CD45R (B cells) are significantly increased relative to wild-type hearts
• heart inflammation is already detectable at 6 months of age when cardiac structure and function are normal
• RT-PCR analysis showed significantly enhanced interleukin-6 (IL-6) mRNA expression in mutant hearts relative to wild-type controls
• however, no significant difference in interleukin-1beta (IL-1beta) mRNA expression is observed
• RT-PCR analysis showed significantly enhanced TNF mRNA expression in mutant hearts relative to wild-type controls

homeostasis/metabolism
• at 10 months of age, mutant hearts accumulate autophagosomes, as shown by enhanced protein abundance of LC3 II; LC3 immunofluorescence and ultrastructural analysis confirmed accumulation of autophagic vacuoles in mutant hearts
• p62 (a marker for autophagic flux), is significantly increased in mutant hearts, indicating impaired autophagic flux
• the observed increase of LC3 II protein levels in mutant hearts is not further enhanced by treatment with chloroquine (an inhibitor of autophagosome-lysosome fusion)
• mutant MEFs show significantly increased LC3 II protein levels; however, the increase in LC3 II protein levels is not further enhanced by bafilomycin A1 (an autophagosome-lysosome fusion inhibitor), suggesting that autophagic flux is impaired in mutant MEFs
• ultrastructural analysis of mutant MEFs revealed clustered double-membrane autophagosomes and complex vacuoles containing multiple layers of membrane
• RT-PCR analysis showed significantly enhanced interleukin-6 (IL-6) mRNA expression in mutant hearts relative to wild-type controls
• however, no significant difference in interleukin-1beta (IL-1beta) mRNA expression is observed
• RT-PCR analysis showed significantly enhanced TNF mRNA expression in mutant hearts relative to wild-type controls

muscle
• by 10 months of age, the cross-sectional area of individual cardiomyocytes is significantly increased relative to wild-type controls
• by 10 months of age, ejection fraction (EF) and percent fractional shortening (%FS) are reduced, suggesting impaired cardiac function
• homozygotes are viable, fertile, and developmentally normal but develop age-related cardiomyopathy, evident by 10 months of age
• no alterations in cardiac structure are noted at 2 and 6 months of age
• by 10 months of age, mutant hearts show significantly increased apoptosis, as shown by TUNEL analysis

growth/size/body
• by 10 months of age, mutant hearts appear to be larger than wild-type





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
11/12/2024
MGI 6.24
The Jackson Laboratory